https://doi.org/10.4081/itjm.2022.1553

Clinical significance of salivary, serum, nitric oxide, and arginase in breast cancer

Vol. 16 No. 1 (2022)
Submitted: 21 November 2022
Accepted: 5 December 2022
Published: 30 December 2022
Nitric oxide, arginase, saliva, breast cancer.
Abstract Views: 754
PDF: 196
HTML: 50
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Araz M. Yousif
Basic Science Department, Dentistry College, Hawler Medical University, Erbil, Iraq.
Parween A. Ismail
parween.ismail@su.edu.krd
Chemistry Department, Education College, Salahaddin University, Erbil, Iraq.

Breast cancer is the most commonly diagnosed cancer among females. A source of sampling for clinical diagnosis is saliva which has been utilized and it is a promising approach as collecting saliva is relatively easy and non-invasive. Over the past two decades, utilizing saliva as a biomarker, specifically for early cancer diagnosis has attracted much research interest. The aim was to alter the sample collection from blood to saliva for some components such as nitric oxide (NO) and arginase, in order to detect an easy, earlier and noninvasive diagnostic test as biomarkers and prognostic tools in patients with breast cancer. A total of 73 female volunteers were participated in this study, 25 healthy volunteers compared with 48 patients with breast cancer in order to estimate and compare both salivary and blood level components such as NO and arginase. The mean blood and salivary samples for both nitric oxide and arginase levels were significantly raised in patients with breast cancer when they compared with controls (P<0.001). In this study the changing of salivary levels of NO and arginase as compared with blood may be used as a non-invasive diagnostic tool alternative to serum testing component, which were significantly increased in patients with breast cancer in both blood and saliva and also, may be used as biomarkers and tumor progression tests in diagnosing of breast cancer.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Yousif AM, Ismail PA, Ismail NA. Steroid hormones, immunoglobulins and some biochemical parameters changes in patients with breast cancer. DJM 2016;10:1-8.
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
Chlebowski RT, Manson JE, Anderson GL, et al. Estrogen plus progestin and breast cancer incidence and mortality in the women’s health initiative observational study. J Natl Cancer Inst 2013;105:526-35.
LY Yu, Tang J, Zhang C, et al. New immunotherapy strategies in breast cancer. Int J Environ Res Public Health 2017;14:1-18.
Lannin DR, Wang S. Are small breast cancers good because they are smallor small because they are good? N Engl J Med 2017;376:2286-91.
Welch HG, Prorok PC, O’Malley AJ, Kramer BS. Breast-cancer tumor size, over diagnosis, and mammography screening effectiveness. N Engl J Med 2016;375:1438-47.
Singh R, Pervin S, Karimi A, et al. Arginase activity in human breast cancer cell lines: N-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosisin MDA-MB-468Cells1. Cancer Res 2000;60:3305-12.
Rodriguez PC, Quiceno DG, Zabaleta J, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibitsT-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004;64:5839-49.
Maarsingh H, Zaagsma J. Arginase and asthma: novel insights into nitric oxide homeostasis and airway hyperresponsiveness. Trends Pharmacol Sci 2003;24:450-55.
Bogdan C. Nitric oxide and the immune response. Nature Immunol 2001;2:907-16.
Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumor progression. Nat Rev Cancer 2006;6:521-34.
Rapado-González Ó, Majem B, Muinelo-Romay L, et al. Cancer salivary biomarkers for tumours distant to the oral cavity. Int J Mol Sci 2016;17:1531-52.
Abu Kasimi N, Zainal Ariffini SH, Hahni MA, et al. Stability of lactate dehydrogenase, aspartate aminotransferase, alkaline phosphatase and tartarateresistant acid phosphatase in human saliva and gingival creviculfluid in the presence of protease inhibitopr. Arch Biol Sci Belgrade 2013;65:1131-40.
Dhivyalakshmi M, Maheswari TNU. Expression of salivary biomarkers-alkaline phosphatase andlactate dehydrogenase in oral leukoplakia. Int J ChemTech Res 2014;6:3014-18.
Crombez EA, Cederbaum SD. Hyperargininemia due to liver arginase deficiency. Mol Genet Metab 2005;84:243-51.
Harris M, Taylor G. Medical statistics made easy. USA: Martin Duntiz; 2004.
Larrea E, Sole C, Manterola L, et al. New concepts in cancer biomarkers: circulating miRNAs in liquid biopsies. Int J Mol Sci 2016;17:627-69.
Dhivyalakshmi M, Maheswari TNU. Expression of salivary biomarkers-alkaline phosphatase andlactate dehydrogenase in oral Leukoplakia. IntJ ChemTech Res 2014;6:3014-18.
Chen D, Song N, Ni R, et al. Saliva as a sampling source for the detection of leukemic fusiontranscripts. J Transl Med 2014;12:321-25.
Shenoy SB, Shenoy P, Talwar A, et al. Evaluation of salivary enzymes in post-menopausal women with and without periodontitis. NUJHS 2014;4:88-91.
Pujari KN, Jadkar SP. Superoxide dismutase levels in leukemia’s. Int J Med Sci 2011;2:96-100.
Joshi PS, Chougule M, Dudanakar M, Golgire S. Comparison between salivary and serum lactate dehydrogenase levels in patients with oral leukoplakia and oral squamous cell carcinoma - A pilot study. Int J Oral Max Path 2012;3:07-12.
Pervin S, Singh R, Freije WA, Chaudhuri G. MKP-1- Induced dephosphorylation of extracellular signal-regulated kinase is essential for triggering nitric oxide-induced apoptosis in human breast cancer cell lines:implications in breast cancer. Cancer Res 2003;63:8853-60.
Pervin SR, Chaudhuri G. Nitric oxide, Nω-hydroxy-l-arginine and breast cancer. Nitric Oxide 2008;19:103-6.
Lechner M, Lirk P, Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin Cancer Bio 2005;15:277-89.
Pervin S, Singh R, Hernandez E, Wu G, Chaudhuri G. Nitric oxidein physiologic concentrations targets the translational nachinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway. Cancer Res 2007;67:289-99.
Weigert A, Brüne B. Nitric oxide, apoptosis and macrophage polarization during tumor progression. Nitric Oxide 2008;19:95-02.
Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 2008;68:2561-63.
Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. JEM 2005;202:931-9.
Chang C-I, Liao JC, Kuo L. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res 2001;61:1100-6.
Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007;13:721s-6s.

How to Cite

Yousif, A. M., & Ismail, P. A. (2022). Clinical significance of salivary, serum, nitric oxide, and arginase in breast cancer. Italian Journal of Medicine, 16(1). https://doi.org/10.4081/itjm.2022.1553
Copyright (c) 2022 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.